Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 11, 2021
Share
Easywell Biomedicals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 42.01 million compared to TWD 35.12 million a year ago. Net loss was TWD 50.43 million compared to TWD 52.77 million a year ago. Basic loss per share from continuing operations was TWD 0.4429 compared to TWD 0.5429 a year ago. Basic loss per share was TWD 0.4429 compared to TWD 0.5429 a year ago.
For the nine months, sales was TWD 160.18 million compared to TWD 180.75 million a year ago. Net loss was TWD 106.81 million compared to TWD 152.89 million a year ago. Basic loss per share from continuing operations was TWD 1.0286 compared to TWD 1.6714 a year ago. Basic loss per share was TWD 1.0286 compared to TWD 1.6714 a year ago.
Easywell Biomedicals Inc. is a Taiwan-based company principally engaged in the research, development, production and sale of raw materials and temperature measurement products. The raw materials are applied in the manufacture of medicament for the treatment of epilepsy, pain and fever, antihypertensive and diuretic, skeletal muscle relaxants, among others. The Company's diagnostic devices include ear thermometers and digital clinical thermometers. The Company distributes its products mainly in Taiwan, the Americas and Europe.
EASYWELL BIOMEDICALS, INC. 
